Den Europæiske Union - dansk - EMA (European Medicines Agency)

baxter holding b.v. - doxorubicinhydrochlorid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastiske midler - caelyx pegyleret liposomal er anført:som monoterapi til patienter med metastatisk brystkræft, hvor der er en øget cardiac risiko;til behandling af fremskreden kræft i æggestokkene hos kvinder, der har undladt en første linje platin-baseret kemoterapi, og i kombination med bortezomib til behandling af progressive myelomatose patienter, der har modtaget mindst én tidligere behandling, og som allerede har gennemgået eller er uegnet for bone marrow transplantation;til behandling af aids-relateret kaposis sarkom (ks) i patienter med lavt cd4-tæller (.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - prostatiske neoplasmer - terapeutiske radioaktive lægemidler - xofigo er indiceret til behandling af voksne med kastreringsresistent prostatacancer, symptomatiske knoglemetastaser og ingen kendte viscerale metastaser.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - incivo, i kombination med peginterferon alfa og ribavirin, er indiceret til behandling af genotype-1 kronisk hepatitis c hos voksne patienter med kompenseret leversygdom (herunder skrumpelever):der er i behandling naive;som tidligere er blevet behandlet med interferon alfa (pegyleret eller non-pegyleret) alene eller i kombination med ribavirin, herunder relapsers, delvis respondenter og respondenter null.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

les laboratoires servier - strontiumranelat - osteoporose, postmenopausale - narkotika til behandling af knoglesygdomme - behandling af alvorlig osteoporose hos postmenopausale kvinder med høj risiko for brud for at reducere risikoen for hvirvel og hoftefrakturer. behandling af svær osteoporose hos voksne mænd med øget risiko for fraktur. beslutningen om at ordinere strontium ranelate bør være baseret på en vurdering af den enkelte patients samlede risici.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

les laboratoires servier - strontiumranelat - osteoporose, postmenopausale - narkotika til behandling af knoglesygdomme - behandling af alvorlig osteoporose hos postmenopausale kvinder med høj risiko for brud for at reducere risikoen for hvirvel og hoftefrakturer. behandling af svær osteoporose hos voksne mænd med øget risiko for fraktur. beslutningen om at ordinere strontium ranelate bør være baseret på en vurdering af den enkelte patients samlede risici.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland - prucalopride tocopherolsuccinat hidrørende - forstoppelse - andre stoffer til forstoppelse - resolor er indiceret til symptomatisk behandling af kronisk forstoppelse hos voksne, hvor afføringsmidler ikke giver tilstrækkelig lindring.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. for yderligere information om human epidermal vækstfaktor receptor 2 (her2) status henvises til afsnit 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. for yderligere oplysninger om her2-status henvises til afsnit 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiske midler - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.